144 related articles for article (PubMed ID: 24267274)
1. Two birds with one stone: dual p110δ and p110γ inhibition.
Okkenhaug K
Chem Biol; 2013 Nov; 20(11):1309-10. PubMed ID: 24267274
[TBL] [Abstract][Full Text] [Related]
2. PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models.
Winkler DG; Faia KL; DiNitto JP; Ali JA; White KF; Brophy EE; Pink MM; Proctor JL; Lussier J; Martin CM; Hoyt JG; Tillotson B; Murphy EL; Lim AR; Thomas BD; Macdougall JR; Ren P; Liu Y; Li LS; Jessen KA; Fritz CC; Dunbar JL; Porter JR; Rommel C; Palombella VJ; Changelian PS; Kutok JL
Chem Biol; 2013 Nov; 20(11):1364-74. PubMed ID: 24211136
[TBL] [Abstract][Full Text] [Related]
3. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.
Balakrishnan K; Peluso M; Fu M; Rosin NY; Burger JA; Wierda WG; Keating MJ; Faia K; O'Brien S; Kutok JL; Gandhi V
Leukemia; 2015 Sep; 29(9):1811-22. PubMed ID: 25917267
[TBL] [Abstract][Full Text] [Related]
4. Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection.
Pillinger G; Loughran NV; Piddock RE; Shafat MS; Zaitseva L; Abdul-Aziz A; Lawes MJ; Bowles KM; Rushworth SA
Oncotarget; 2016 Jun; 7(26):39784-39795. PubMed ID: 27174919
[TBL] [Abstract][Full Text] [Related]
5. IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells.
Dong S; Guinn D; Dubovsky JA; Zhong Y; Lehman A; Kutok J; Woyach JA; Byrd JC; Johnson AJ
Blood; 2014 Dec; 124(24):3583-6. PubMed ID: 25258342
[TBL] [Abstract][Full Text] [Related]
6. P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse.
Iyengar S; Clear A; Bödör C; Maharaj L; Lee A; Calaminici M; Matthews J; Iqbal S; Auer R; Gribben J; Joel S
Blood; 2013 Mar; 121(12):2274-84. PubMed ID: 23341541
[TBL] [Abstract][Full Text] [Related]
7. The Selective Phosphoinoside-3-Kinase p110δ Inhibitor IPI-3063 Potently Suppresses B Cell Survival, Proliferation, and Differentiation.
Chiu H; Mallya S; Nguyen P; Mai A; Jackson LV; Winkler DG; DiNitto JP; Brophy EE; McGovern K; Kutok JL; Fruman DA
Front Immunol; 2017; 8():747. PubMed ID: 28713374
[TBL] [Abstract][Full Text] [Related]
8. Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma.
Horwitz SM; Koch R; Porcu P; Oki Y; Moskowitz A; Perez M; Myskowski P; Officer A; Jaffe JD; Morrow SN; Allen K; Douglas M; Stern H; Sweeney J; Kelly P; Kelly V; Aster JC; Weaver D; Foss FM; Weinstock DM
Blood; 2018 Feb; 131(8):888-898. PubMed ID: 29233821
[TBL] [Abstract][Full Text] [Related]
9. Specific inhibition of PI3K p110δ inhibits CSF-1-induced macrophage spreading and invasive capacity.
Mouchemore KA; Sampaio NG; Murrey MW; Stanley ER; Lannutti BJ; Pixley FJ
FEBS J; 2013 Nov; 280(21):5228-36. PubMed ID: 23648053
[TBL] [Abstract][Full Text] [Related]
10. The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases.
Banham-Hall E; Clatworthy MR; Okkenhaug K
Open Rheumatol J; 2012; 6():245-58. PubMed ID: 23028409
[TBL] [Abstract][Full Text] [Related]
11. p110gamma and p110delta isoforms of phosphoinositide 3-kinase differentially regulate natural killer cell migration in health and disease.
Saudemont A; Garçon F; Yadi H; Roche-Molina M; Kim N; Segonds-Pichon A; Martín-Fontecha A; Okkenhaug K; Colucci F
Proc Natl Acad Sci U S A; 2009 Apr; 106(14):5795-800. PubMed ID: 19297623
[TBL] [Abstract][Full Text] [Related]
12. Taking PI3Kδ and PI3Kγ one step ahead: dual active PI3Kδ/γ inhibitors for the treatment of immune-mediated inflammatory diseases.
Rommel C
Curr Top Microbiol Immunol; 2010; 346():279-99. PubMed ID: 20593311
[TBL] [Abstract][Full Text] [Related]
13. The catalytic PI3K isoforms p110gamma and p110delta contribute to B cell development and maintenance, transformation, and proliferation.
Beer-Hammer S; Zebedin E; von Holleben M; Alferink J; Reis B; Dresing P; Degrandi D; Scheu S; Hirsch E; Sexl V; Pfeffer K; Nürnberg B; Piekorz RP
J Leukoc Biol; 2010 Jun; 87(6):1083-95. PubMed ID: 20200404
[TBL] [Abstract][Full Text] [Related]
14. Ligand-selective signal transduction by two endogenous GnRH isoforms involves biased activation of the class I PI3K catalytic subunits p110β, p110γ, and p110δ in pituitary gonadotropes and somatotropes.
Pemberton JG; Stafford JL; Chang JP
Endocrinology; 2015 Jan; 156(1):218-30. PubMed ID: 25343277
[TBL] [Abstract][Full Text] [Related]
15. Deficiency of PI3-Kinase catalytic isoforms p110γ and p110δ in mice enhances the IL-17/G-CSF axis and induces neutrophilia.
Bucher K; Schmitt F; Mothes B; Blumendeller C; Schäll D; Piekorz R; Hirsch E; Nürnberg B; Beer-Hammer S
Cell Commun Signal; 2017 Jul; 15(1):28. PubMed ID: 28724384
[TBL] [Abstract][Full Text] [Related]
16. PI3K/p110{delta} is a novel therapeutic target in multiple myeloma.
Ikeda H; Hideshima T; Fulciniti M; Perrone G; Miura N; Yasui H; Okawa Y; Kiziltepe T; Santo L; Vallet S; Cristea D; Calabrese E; Gorgun G; Raje NS; Richardson P; Munshi NC; Lannutti BJ; Puri KD; Giese NA; Anderson KC
Blood; 2010 Sep; 116(9):1460-8. PubMed ID: 20505158
[TBL] [Abstract][Full Text] [Related]
17. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.
Lannutti BJ; Meadows SA; Herman SE; Kashishian A; Steiner B; Johnson AJ; Byrd JC; Tyner JW; Loriaux MM; Deininger M; Druker BJ; Puri KD; Ulrich RG; Giese NA
Blood; 2011 Jan; 117(2):591-4. PubMed ID: 20959606
[TBL] [Abstract][Full Text] [Related]
18. Novel phosphoinositide 3-kinase δ,γ inhibitor: potent anti-inflammatory effects and joint protection in models of rheumatoid arthritis.
Boyle DL; Kim HR; Topolewski K; Bartok B; Firestein GS
J Pharmacol Exp Ther; 2014 Feb; 348(2):271-80. PubMed ID: 24244039
[TBL] [Abstract][Full Text] [Related]
19. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
Wallace DJ; Furie RA; Tanaka Y; Kalunian KC; Mosca M; Petri MA; Dörner T; Cardiel MH; Bruce IN; Gomez E; Carmack T; DeLozier AM; Janes JM; Linnik MD; de Bono S; Silk ME; Hoffman RW
Lancet; 2018 Jul; 392(10143):222-231. PubMed ID: 30043749
[TBL] [Abstract][Full Text] [Related]
20. Reduction in Renal Ischemia-Reperfusion Injury in Mice by a Phosphoinositide 3-Kinase p110gamma-Specific Inhibitor.
Kim N; Woo DC; Joo SJ; Song Y; Lee JJ; Woo CW; Kim ST; Hong S; Cho YM; Han DJ
Transplantation; 2015 Oct; 99(10):2070-6. PubMed ID: 26431158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
